Diener_subbed.qxp 5/2/09 9:22 am Page 35
Developments in Secondary Stroke Prevention
14. Mohr JP, Thompson JLP, Lazar RM, et al., A comparison of aldosterone system: cardiorenal effects and implications for 2008;26(3):544–52.
warfarin and aspirin for the prevention of recurrent ischemic renal and cardiovascular disease states, Am J Med Sci, 58. Fagan SC, Kozak A, Hill WD, et al., Hypertension after
stroke, N Engl J Med, 2001;345:1444–51. 2003;326:15–24. experimental cerebral ischemia: candesartan provides
15. The ESPRIT Study Group, Medium intensity oral anticoagulants 36. Dahlöf B, Devereux RB, Kjeldsen SE, et al., Cardiovascular neurovascular protection, J Hypertens, 2006;24:535–9.
versus aspirin after cerebral ischaemia of arterial origin morbidity and mortality in the Losartan Intervention for 59. Faure S, Oudart N, Javellaud J, et al., Synergistic protective
(ESPRIT): a randomised controlled trial, Lancet Neurol, Endpoint reduction in hypertension study (LIFE): a randomised effects of erythropoietin and olmesartan on ischemic stroke
2007;6(2):115–24. trial against atenolol, Lancet, 2002;359:995–1003. survival and post-stroke memory dysfunctions in the gerbil, J
16. CAPRIE Steering Committee, A randomised, blinded, trial of 37. Schrader J, Lüders S, Kulschewski A, et al., Morbidity and Hypertens, 2006;24:2255–61.
clopidogrel versus aspirin in patients at risk of ischaemic events Mortality after Stroke, Eprosartan compared with nitrendipine 60. Engelhorn T, Doerfler A, Heusch G, et al., Reduction of cerebral
(CAPRIE), Lancet, 1996;348:1329–39. for secondary prevention: principal results of a prospective infarct size by the AT1-receptor candesartan, the HMG-CoA
17. The Clopidogrel in Unstable Angina to Prevent Recurrent Events randomized controlled study (MOSES), Stroke, reductase inhibitor rosuvastatin and their combination, An
Trial Investigators, Effects of clopidogrel in addition to aspirin in 2005;36:61218–26. experimental study in rats, Neurosci Lett, 2006;406:92–6.
patients with acute coronary syndromes without ST-segment 38. Schrader J, Lüders S, Kulschewski A, et al., The ACCESS Study: 61. Groth W, Blume A, Gohlke P, et al., Chronic pre-treatment with
elevation, N Engl J Med, 2001;345:494–502. evaluation of acute candesartan cilexetil therapy in stroke candesartan improves recovery from focal cerebral ischaemia in
18. Steinhubl SR, Berger PB, Mann JT III, et al., Early and sustained survivors, Stroke, 2003;34:2699–703. rats, J Hypertens, 2003;21:2175–82.
dual oral antiplatelet therapy following percutaneous coronary 39. The ONTARGET Investigators, Telmisartan, ramipril, or both in 62. Thone-Reineke C, Zimmermann M, Neumann C, et al., Are
intervention: a randomized controlled trial, JAMA, 2002;288: patients at high risk for vascular events, N Engl J Med, angiotensin receptor blockers neuroprotective?, Curr Hypertens
2411–20. 2008;358: 1547–59. Rep, 2004;6:257–66.
19. Diener H-C, Bogousslavsky J, Brass LM, et al., Aspirin and 40. Pfeffer MA, McMurray JJV, Velazquez EJ, et al., Valsartan, 63. Lee JH, Lack of antiapoptotic effects of an antiplatelet drug,
clopidogrel compared with clopidogrel alone after recent captopril, or both in myocardial infarction complicated by heart aspirin and clopidogrel, and antioxidant, MCI-186, against focal
ischaemic stroke or transient ischaemic attack in high-risk failure, left ventricular dysfunction, or both, N Engl J Med, 2003; ischemic brain damage in rats, Neurol Res, 2005;27:483–92.
patients (MATCH): randomised, double-blind, placebo-controlled 349:1893–1906. 64. Paciaroni M, Agnelli G, Caso V, et al., Prior use of
trial, Lancet, 2004;364:331–7. 41. Diener HC, Sacco R, Yusuf S for the Steering Committee and antithrombotic agents and neurological functional outcome at
20. Bhatt DL, Fox KA, Hacke W, et al., Clopidogrel and aspirin PRoFESS Study Group, Rationale, design and baseline data of a discharge in patients with ischemic stroke, J Thromb Haemost,
versus aspirin alone for the prevention of atherothrombotic randomized, double-blind, controlled trial comparing two 2006;4: 1957–61.
events, N Engl J Med, 2006;354:1706–17. antithrombotic regimens (a fixed-dose combination of 65. Sivenius J, Cunha L, Diener HC, et al., Antiplatelet treatment
21. Bhatt DL, Flather MD, Hacke W, et al., Patients with prior extended-release dipyridamole plus ASA with clopidogrel) and does not reduce the severity of subsequent stroke. European
myocardial infarction, stroke, or symptomatic peripheral arterial telmisartan versus placebo in patients with strokes: The Stroke Prevention Study 2 Working Group, Neurology,
disease in the CHARISMA trial, J Am Coll Cardiol, 2007;49: Prevention Regimen for Effectively Avoiding Second Strokes Trial 1999;53(4):825–9.
1982–8. (PRoFESS), Cerebro Dis, 2007;23:368–380. 66. Aldandashi S, Noor R, Wang CX, et al., Combination treatment
22. Diener HC, Cunha L, Forbes C, et al., European Stroke 42. Sacco RL, Diener H-C, Yusuf S, et al., Aspirin and extended- with dipyridamole, aspirin, and tPA in an embolic model of
Prevention Study 2. Dipyridamole and acetylsalicylic acid in the release dipyridamole versus clopidogrel for recurrent stroke, N stroke in rats, Exp Neurol, 2007;205:563–8.
secondary prevention of stroke, J Neurol Sci, 1996;143:1–13. Engl J Med, 2008;359(12):1238–51. 67. Feigin V, Ratnasabapathy Y, Anderson C, Does blood pressure
23. Guiraud-Chaumeil B, Rascol A, David J, et al., Prévention des 43. Akhtar M, Ordovas K, Martin A, et al., Effect of chronic lowering treatment prevents dementia or cognitive decline in
récidives des accidents vasculaires cérébraux ischémiques par sustained-release dipyridamole on myocardial blood flow and patients with cardiovascular and cerebrovascular disease?,
les anti-agrégants plaquettaires Résultats d’un essai left ventricular function in patients with ischemic J Neurol Sci, 2005;229–230:151–5.
thérapeutique controlé de 3 ans, Rev Neurol (Paris), cardiomyopathy, Conges Heart Fail, 2007;13:130–35. 68. The PROGRESS Collaborative Group, Effects of blood pressure
1982;138:367–85. 44. Hirsh J, Guyatt G, Albers GW, et al.,The seventh ACCP lowering with perindopril and indapamide therapy on dementia
24. Bousser MG, Eschwege E, Haguenau M, et al., ‘AICLA’ conference on antithrombotic and thrombolytic therapy: and cognitive decline in patients with cerebrovascular disease,
controlled trial of aspirin and dipyridamole in the secondary evidence-based guidelines, Chest, 2004;126(Suppl. 1):S172–3. Arch Intern Med, 2003;163:1069–75.
prevention of atherothrombotic cerebral ischemia, Stroke, 45. Yusuf S, Phil D, Diener H-C, et al., Telmisartan to prevent 69. Forette F, Seux M, Staessen J, et al., Prevention of dementia in
1983;14:5–14. recurrent stroke and cardiovascular events, N Engl J Med, randomised double-blind placebo-controlled Systolic Hypertension
25. American-Canadian Co-operative Study Group, Persantin aspirin 2008;359 (12):1225–37. in Europe (Syst-Eur) trial, Lancet, 1998;352:1347–51.
trial in cerebral ischemia. Part II: Endpoint results, Stroke, 1985; 46. Jandeleit-Dahm KA, Tikellis C, Reid CM, et al., Why blockade of 70. Lithell H, Hansson L, Skoog I, et al., for the SCOPE Study Group,
16:406–15. the renin-angiotensin system reduces the incidence of new- The Study on Cognition and Prognosis in the Elderly (SCOPE):
26. Kaye J, A trial to evaluate the relative roles of dipyridamole and onset diabetes, J Hypertens, 2005;23:463–73. principal results of a randomised double-blind intervention trial,
aspirin in the prevention of deep vein thrombosis in stroke 47. Ruilope LM, Segura J, Losartan and other angiotensin II J Hypertens, 2003;21:875–86.
patients, Bracknell, Berkshire: Boehringer Ingelheim, 1990. antagonists for nephropathy in type 2 diabetes mellitus: a 71. Diener H-C, Sacco RL, Yusuf S, et al., Effects of aspirin plus
27. Algra A, Van Gijn J, Algra A, et al.,Secondary prevention after review of the clinical trial evidence, Clin Ther, extended-release dipyridamole versus clopidogrel and
cerebral ischaemia of presumed arterial origin: is aspirin still the 2003;25:3044–64. telmisartan on disability and cognitive function after recurrent
touchstone?, J Neurol Neurosurg Psychiatry, 1999;66(5):557–9. 48. Silverstein RL, Fenves AZ, Ram CV, ARBs and target organ stroke in patients with ischaemic stroke in the Prevention
28. The ESPRIT Study Group, Aspirin plus dipyridamole versus protection. Exploring benefits beyond their antihypertensive Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial:
aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): effects, Postgrad Med, 2004;116:31–8. a double-blind, active and placebo-controlled study, Lancet
randomised controlled trial, Lancet, 2006;1367:1665–73. 49. Lenzi GL, Altieri M, Maestrini I, Post-stroke depression, Rev Neurol, 2008; 7(10):875–84.
29. Rodgers A, MacMahon S, Gamble G, et al., Blood pressure and Neurol (Paris), 2008;164(10):837–40. 72. Rankin J, Cerebral vascular accidents in patients over the age of
risk of stroke in patients with cerebrovascular disease, The 50. De Keyser J, Uyttenboogaart M, Koch MW, et al., Neuroprotection 60, II: prognosis, Scot Med J, 1957;2:200–15.
United Kingdom Transient Attack Collaborative Group, BMJ, in acute ischemic stroke, Acta Neurol Belg, 2005;105:144–48. 73. Mahoney FI, Barthel DW, Functional evaluation: The Barthel
1996;313: 147. 51. Schabitz WR, Fisher M, Perspectives on neuroprotective stroke Index, Md State Med J, 1965;14:61–5.
30. Blood Pressure Lowering Treatment Trialists’ Collaboration, therapy, Biochem Soc Trans, 2006;34:1271–6. 74. Folstein M, Folstein S, McHugh PR, Mini-mental state: a
Effects of different blood-pressure-lowering regimens on major 52. Hill MD, Stroke: the dashed hopes of neuroprotection, Lancet practical method for grading the cognitive state of patients for
cardiovascular events: results of prospectively designed Neurol, 2007;6:2–3. the clinician, J Psychiatr Res, 1975;12:189–98.
overviews of randomised trials, Lancet, 2003;362:1527–35. 53. Blake AD, Dipyridamole is neuroprotective for cultured rat 75. Guo S, Kim WJ, Lok J, et al., Neuroprotection via matrix-trophic
31. PROGRESS Collaborative Group, Randomised trial of a perindopril- embryonic cortical neurons, Biochem Biophys Res Commun, coupling between cerebral endothelial cells and neurons, Proc
based blood-press-lowering regimen among 6105 individuals with 2004; 314(2):501–4. Natl Acad Sci U S A, 2008;105:7582–7.
previous stroke or transient ischaemic attack, Lancet, 2001;358: 54. Farinelli SE, Green LA, Friedman WJ, Neuroprotective actions of 76. The ACTIVE Steering Committee, Rationale and design of
1033–41. Errata, Lancet, 2001;358:1556, 2002;359:2120. dipyridamole on cultured CNS neurons, J Neurosci, 1998;18(14): ACTIVE: the atrial fibrillation clopidgrel trial with irbesartan for
32. The Heart Outcomes Prevention Evaluation Study Investigators, 5112–23. prevention of vascular events, Am Heart J, 2006;151:1187–93.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, 55. Zheng Z, Schwab S, Grau A, et al., Neuroprotection by early and 77. Teo K, Yusuf S, Sleight P, et al., Rationale, design and baseline
on cardiovascular events in high-risk patients, N Engl J Med, delayed treatment of acute stroke with high dose aspirin, Brain characteristics of two large, simple randomized trials evaluating
2000; 342:145–53. Errata, N Engl J Med, 2000;342:748, 1736. Res, 2007;1186:275–80. telmisartan, ramipril and their combination in high-risk patients:
33. Kaschina E, Unger T, Angiotensin AT1/AT2 receptors: regulation, 56. Gomes I, Aspirin: a neuroprotective agent at high doses?, Natl the Ongoing Telmisartan Alone and in combination with
signalling and function, Blood Press, 2003;12:70–88. Med J India, 1998;11(1):14–17. Ramipril Global Endpoint Trial/Telmisartan Randomized
34. Schmieder RE, Mechanisms for the clinical benefits of angiotensin 57. Krikov M, Thone-Reineke C, Müller S, et al., Candesartan but Assessment Study in ACE Intolerant Subjects with
II receptor blockers, Am J Hypertens, 2005;18:720–30. not ramipril pretreatment improves outcome after stroke and Cardiovascular Disease (ONTARGET/TRANSCEND) trials, Am
35. Brewster UC, Setaro JF, Perazella MA, The renin-angiotensin- stimulates neurotrophin BNDF/TrkB system in rats, J Hypertens, Heart J, 2004;148:52–61.
US NEUROLOGY 35
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84